Gland Pharma Limited – Investor Presentation Summary
Key Operational Highlights
- Revenue from operations reached ₹18,003 Mn in Q1 FY27, representing 20% YoY growth.
- Launched 4 new molecules in the USA market, including Multi-Vitamin and Leucovorin calcium.
- Filed 3 ANDAs and received approval for 7 ANDAs in Q1 FY27.
- Cumulative ANDA filings reached 389 in the U.S. (342 approved, 47 pending).
- Ready-to-Use (RTU) Bags portfolio addresses a market opportunity of approximately $644 million in the US.
Key drivers of operational performance: CDMO growth supported by recent product launches; B2B growth supported by increased demand from existing customers and higher volumes.
Segment-wise Performance
Not Specified
Financial Highlights
Revenue: ₹18,003 Mn
EBITDA: ₹4,930 Mn
PAT: ₹3,170 Mn
Gross Profit: ₹11,759 Mn
Gross Profit margin: 65%
EBITDA margin: 27%
Adjusted EBITDA: ₹5,102 Mn
Adjusted EBITDA margin: 28%
PBT: ₹4,350 Mn
PBT margin: 24%
PAT margin: 18%
YoY/QoQ comparison: Revenue grew 20% YoY (from ₹15,056 Mn in Q1 FY26) and 3% QoQ (from ₹17,428 Mn in Q4 FY26). PAT increased 47% YoY (from ₹2,155 Mn) but declined 14% QoQ (from ₹3,667 Mn).
Drivers of financial performance: Higher revenue growth and operational efficiencies.
Comparison to market estimates: Not Specified
Key Risks: Not Specified
Geographical Revenue Split
Domestic vs Export/Regional Revenue:
- Europe Contribution: 22% of Q1 FY27 revenue
- India Contribution: 4% of Q1 FY27 revenue
- Other Core Markets (Canada, Australia and New Zealand): Revenue declined due to volume reduction in existing products
- Rest of the World: Growth seen across key products including Heparin, Huminsulin and Rocuronium Bromide
Regional Breakdown:
- US Market: Growth driven by recent CDMO product launches (Dalbavancin and Multi-Vitamin) and B2B volume expansion in existing products (Enoxaparin, Vancomycin, Chlorothiazide and Heparin)
- Europe Market: Volume expansion in existing products including Daptomycin and Cenexi CDMO products, plus recent Dalbavancin launch
- India Market: Growth in CDMO for certain products including Huminsulin; decline in B2B due to lower sales of Enoxaparin
Balance Sheet Snapshot
Not Specified
Capex & Cash Flow Health
Capital Expenditure: Not Specified for Q1 FY27
Cash Flow from Operations: Not Specified for Q1 FY27
Free Cash Flow: Not Specified
Operating Cash Flow: Not Specified
Net Debt Movement: Not Specified
Investment Rationale: Focus on complex product development and capacity expansion through strategic partnerships.
Strategic & R&D Initiatives
Investments in Innovation: R&D expenses were ₹772 million in Q1 FY27 (4% of consolidated revenue), focused on complex product development and number of filings.
Expected impact on growth: Six complex injectable products already launched with three more in line for approval; complex injectables expected to remain central pillar of long-term growth.
Strategic Rationale:
- Fifteen products in co-development (seven 505(b)(2) and eight ANDAs) with commercialization anticipated to begin in FY28
- CDMO partnership with a Global Pharmaceutical Company: Annualized revenue potential of USD 90-100 million once all products commercialized; technology transfer completion within two years; revenues expected from calendar year 2029
- Strategic collaboration with Neuland Laboratories: Long-term collaboration for manufacturing of sterile APIs for microparticle depot products
- In-licensing agreement with a China-based development company for development, manufacturing and commercialization of a niche liposomal product for U.S. and European markets
Industry Trends & Business Environment
Macro/Industry Trends: Not Specified
Impact on Company: Not Specified
Management Commentary & Growth Outlook
Strategic Outlook: Complex injectables are expected to remain a central pillar of long-term growth, with more products being added to the pipeline.
FY Guidance: Not Specified
Market Share Targets: Not Specified
Risks and Opportunities: Not Specified